NEW YORK, April  02, 2026  (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased ImmunityBio, Inc. (&#34;ImmunityBio&#34; or the &#34;Company&#34;) (NASDAQ:IBRX) securities to contact Lauren Molinaro of Kirby McInerney

IBRX

IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - Contact Kirby McInerney LLP by May 26, 2026

Investors Alerted to Class Action for ImmunityBio Securities Fraud

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, April  02, 2026  (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased ImmunityBio, Inc. (&amp;#34;ImmunityBio&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:IBRX) securities to contact Lauren Molinaro of Kirby McInerney</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Investors in ImmunityBio are being urged to participate in a class action lawsuit following allegations of securities fraud, including misleading representations regarding Anktiva. The FDA&#039;s recent warning letter, which led to a significant drop in share price, could further impact investor sentiment and company valuation.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Investors urged to join class action against ImmunityBio for securities fraud.</li><li>Lawsuit cites misleading claims about Anktiva&#039;s capabilities.</li><li>FDA issued a warning letter about misleading advertising practices.</li><li>ImmunityBio shares fell by 21.2% after FDA&#039;s announcement.</li><li>Lead plaintiff applications must be submitted by May 26, 2026.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>ImmunityBio, Inc. (IBRX)</strong>: Facing lawsuits and FDA scrutiny, impacting share value significantly.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This falls under &#039;Legal&#039; as it involves a class action lawsuit reflecting potential risks associated with ImmunityBio’s communications and claims regarding its products, affecting investor sentiment and stock performance.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>ImmunityBio shares dropped 21.2% post-FDA warning.</li><li>Class action lawsuit may deter new investors.</li><li>Potential investor losses could amplify downward pressure on stock value.</li><li>Ongoing legal scrutiny may prolong recovery timeline for IBRX.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>ImmunityBio&#039;s shares closed at $7.41 on March 24, 2026.</li><li>FDA&#039;s warning letter issued on March 24, 2026, cites misleading claims.</li><li>Investors must apply to be lead plaintiffs by May 26, 2026.</li><li>Class Period for the lawsuit is January 19, 2026, to March 24, 2026.</li><li>Anktiva is marketed as an immunotherapy for cancer treatment.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider shorting IBRX due to ongoing legal risks and declining investor confidence.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">NEW YORK, April  02, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Q93SCQBcPI1--em5uUvAUFld7NdjzrY3-13H6TKjKrs1tid4B4NOg_hI0Q5pvGPiZFs637Es-l-5bnAubw2QAXuTzO6ixz9mavIy4Pzy_Po=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> reminds investors who purchased ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/IBRX">IBRX</a>) securities to contact <a href="https://www.globenewswire.com/Tracker?data=MD-amWcwQTXVW15PlcEH0ZmannPgGlqJ0NLb8HjF7_QGTz2yQPWLxHsIP7DQvY6trO709pOlJYP1xviOlCwV3CCxsVydrGCn2ET9MRlUhjHQwA33x-SSTemS7B3z8crx" rel="nofollow" target="_blank">Lauren Molinaro</a> of Kirby McInerney LLP by email at <a href="https://www.globenewswire.com/Tracker?data=l6nf-k5k0A-cxNksF0j5fhfI_kqNi9lUbPont11pJagrBo5yzHEJPMND096EPJXRwA9IY51xou_ccx3rOjJUfKkmqtWT3IHW8MWi9wP5Z2hRjaqOaARIbxS2lo0-ioJR" rel="nofollow" target="_blank">investigations@kmllp.com</a>, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.</p>  <p align="justify">If you suffered a loss on your ImmunityBio investments, you have until May 26, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.</p>  <p align="justify">Follow the link below for more information about the lawsuit:</p>  <p align="center">[<a href="https://www.globenewswire.com/Tracker?data=CtQjPqEGxFXt805q_8vrLjvek0YFDZYDlYhOGTTXmNmjXEyveml0Pzi3YVL6gljFY9mZ2Ff04b47vEqj8mI9uWkQ7J6Jn-cUy--Yfox2t9TWV8GSVkCzdBz1NkUBlBZaSL05zhLfqc7ZjQ0OEx3Cty5U4Y1JhvHq3aoLjeuzR8k=" rel="nofollow" target="_blank">CONTACT THE FIRM IF YOU SUFFERED A LOSS</a>]</p>  <p align="justify"><strong>What Is The Lawsuit About?</strong></p>  <p align="justify">The lawsuit has been filed on behalf of investors who purchased securities during the period of January 19, 2026 through March 24, 2026, inclusive ("the Class Period"). The lawsuit alleges that (1) Defendant Patrick Soon-Shiong, the Company's Executive Chairman of the Board, materially overstated the capabilities of Anktivas, an FDA-approved IL-15 receptor agonist immunotherapy that combats cancer, in public statements.</p>  <p align="justify">On March 24, 2026, before markets opened, the United States Food and Drug Administration ("FDA") issued a warning letter to ImmunityBio. The FDA stated in the warning letter that a TV ad and podcast, which can be accessed through ImmunityBio's website, has been determined to be "false or misleading." The FDA also stated that "Untitled Letters dated September 9, 2025, and January 7, 2026" were sent to "Altor BioScience, LLC (an indirect wholly-owned subsidiary of ImmunityBio, Inc.) [which] addressed presentations of Anktiva that were, in certain respects, similar to presentations in the TV ad and podcast addressed in this [warning] letter." "[D]espite receiving these previous Untitled Letters, ImmunityBio continues to promote Anktiva in a similarly misleading manner. On this news, the price of ImmunityBio shares declined by $1.99 per share, or approximately 21.2%, from $9.40 per share on March 23, 2026 to close at $7.41 on March 24, 2026.</p>  <p align="center">[<a href="https://www.globenewswire.com/Tracker?data=CPlpQwFhtcaC_48-mhRFv_A0vjx2LH4D3cDMw-gquiNu4_hB5GJcqChYvvcKeJjvTEaXAC-9N9x84V25SvxaWRU1nqeH-P-f1WQZ-_tIaNhNkPDmask2YdPIDBVuGDElpOp6eTSn0WjqQtBtq3jhAgC987IVaPYxiK4IKyu2Z3Jy_tbPr9BUY9xPDnPy_Ukf" rel="nofollow" target="_blank">CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION</a>]</p>  <p align="justify"><strong>What Should I Do?</strong></p>  <p align="justify">If you purchased or otherwise acquired ImmunityBio securities, have information, or would like to learn more about this investigation, please contact <a href="https://www.globenewswire.com/Tracker?data=MD-amWcwQTXVW15PlcEH0WHk7QWGTaq-WjCEF_3oz90KyCJg1E5nFkuNumwNRkw3TJhJKRofbMbG_X-9W88Kpm-SWLp3NgZx-iEygyBXZPR6yeYCu81f7VO58zx9VAQL" rel="nofollow" target="_blank">Lauren Molinaro</a> of<a href="https://www.globenewswire.com/Tracker?data=DVsYUwk3nc8yJs2-PIEehoBOFacntKCztfTdAgKtkt1WUvUmZb5yE9WvkEo7qcJjYj6x7_zW2tfl5nU5xXkQmcQBUlSpUeCm6IMZ_b25fBw=" rel="nofollow" target="_blank"> Kirby McInerney LLP</a> by email at <a href="https://www.globenewswire.com/Tracker?data=l6nf-k5k0A-cxNksF0j5fhfI_kqNi9lUbPont11pJahi0h9VnpHLO6GYkUZJBdF5V59o7foqb9CTxO-OhWOrbIHJMt06fNWQF7Gdt8W2yYPwpXwYuyLtsr4DNB7O6VIJ" rel="nofollow" target="_blank">investigations@kmllp.com</a>, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.</p>  <p align="center"><a href="https://www.globenewswire.com/Tracker?data=HfFcxbUWY1ou0TTCTVCUmgNj0Eg_-a9DZmghZCfRvn1DZi2nqOs5SOHaiQsJcZ12JQQR6D7d2xjFSYgAJOYRHSOrtqpxulKsZ7OMdepWhR7YV319tFRi8f68okDiktay" rel="nofollow" target="_blank">[HOW CAN I PROTECT MY RIGHTS?]</a></p>  <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=Q93SCQBcPI1--em5uUvAUFld7NdjzrY3-13H6TKjKrvU-ME5cVo43qatQLV4eXJzwVZl8_fH5wWNyrtHpdJFq_7ApBURfn-T5C8AOsZY88Y=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's <a href="https://www.globenewswire.com/Tracker?data=Ea4EiwXmlEvsVFTEtfS8VG7Gio49smZwo9UZKvhH78qI2Gls6D8drbzWwrzl5xMmhHQLWpxSywoH2wDzcsy0vw==" rel="nofollow" target="_blank">website</a>.</p>  <p align="justify">This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p>  <p align="justify">Contacts<br></br>Kirby McInerney LLP        <br></br>Lauren Molinaro, Esq.<br></br>212-699-1171<br></br><a href="https://www.globenewswire.com/Tracker?data=yKyj7QrDuVa1VeoYGHHEs3c8XBOR3dWgLEPgI3o7qmghcxP50KnzkflG-5voddY7uDWL45lR5fZ9OdBfY4WQXxBGbmf3hHlJqvBL3SIGZIE=" rel="nofollow" target="_blank">https://www.kmllp.com</a><br></br><a href="https://www.globenewswire.com/Tracker?data=yKyj7QrDuVa1VeoYGHHEs4i645xVgdUAn8VQ_gtTQSziDeFzTTmTkYIjIfwTD8HZ6X3nHZJXkXl_dZ06mOryCeKNSUZjVpJxi70rl9nXbG8tUnukEe-_7Kf0H6slWHr4lDdY0B2lVToootoDt1bnOA==" rel="nofollow" target="_blank">https://securitiesleadplaintiff.com/</a><br></br><a href="https://www.globenewswire.com/Tracker?data=l6nf-k5k0A-cxNksF0j5fhfI_kqNi9lUbPont11pJagEMxRMS3NQWY_KZ5PNTaR-c7Q-cuQFWvfd_GmJXqnCsq0I-nCe3jDBHjlD5m24scIOmK4RFIGozaZSV5Ht_VnL" rel="nofollow" target="_blank">investigations@kmllp.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4MzgxMiM3NTE4NjM1IzIwMjA2Njk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NzNlZmVmYWQtMmQyMC00MjIyLWFkYmQtMjNlMWNhNjQzNGIxLTEwMzE5OTctMjAyNi0wNC0wMy1lbg==/tiny/Kirby-McInerney-LLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/192da1d1-643f-4eee-b850-dde5b9f2b00f"><img src="https://ml.globenewswire.com/media/192da1d1-643f-4eee-b850-dde5b9f2b00f/small/linkedin-logo-300x300-png.png" border="0" width="147" height="147" alt="Primary Logo"></img></a></p>

Investors in ImmunityBio are being urged to participate in a class action lawsuit following allegations of securities fraud, including misleading representations regarding Anktiva. The FDA's recent warning letter, which led to a significant drop in share price, could further impact investor sentiment and company valuation.

IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - Contact Kirby McInerney LLP by May 26, 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News